glp-1 weight loss drugs news today Chart: 1 in 8 Americans Now Use for The next generation of GLP-1

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

Find safe, over-the-counter supplements to support your GLP-1 journey